Skip to Main Content

Author Details

Christopher S Hourigan
and Blood Institute, National Institutes of Health
2001
123
29
PMIDPaper TitleJournal TitlePublished Year
37534515Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.Haematologica2024
38035547Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.Acta Haematol2024
36260702An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.Blood Adv2023
37524919Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification.Leukemia2023
37662423Persistent <i>IDH</i> mutations are not associated with increased relapse or death in patients with <i>IDH</i>-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide.medRxiv2023
37704469Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).Blood Rev2023
37481243Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.Transplant Cell Ther2023
37671649Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.Am J Hematol2023
37353292Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia.Best Pract Res Clin Haematol2023
36949156Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients.Leukemia2023
37180102Prediction of HLA genotypes from single-cell transcriptome data.Front Immunol2023
37406882Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia.Transplant Cell Ther2023
37034683Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.medRxiv2023
37432432DNA Sequencing in Adults With Acute Myeloid Leukemia to Detect Residual Disease Prior to Hematopoietic Cell Transplant-Reply.JAMA2023
36587740Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age â¿¥55 Years.Transplant Cell Ther2023
36881031DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.JAMA2023
36543879Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms.Leukemia2023
36934059Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).Blood Rev2023
36758209How I treat AML incorporating the updated classifications and guidelines.Blood2023
36170795Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms.Blood Adv2023
34547770Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.Blood Adv2022
35368040Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis.Bone Marrow Transplant2022
36485093Achieving MRD negativity in AML: how important is this and how do we get there?Hematology Am Soc Hematol Educ Program2022
36453518The present and future of measurable residual disease testing in acute myeloid leukemia.Haematologica2022
36044658Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism.Blood2022
36335264Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.Leukemia2022
35868306Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell2022
36266326Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.Leukemia2022
36261575Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis.Leukemia2022
35017151Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.J Immunother Cancer2022
35072377Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia.Cancer J2022
35297406Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.Bone Marrow Transplant2022
34587721Utility of plasma cell-free DNA for <i>de novo</i> detection and quantification of clonal hematopoiesis.Haematologica2022
34551064Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.Blood Adv2022
33054127Detectable mutations precede late myeloid neoplasia in aplastic anemia.Haematologica2021
33784346Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review.PLoS One2021
33758317Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.Leukemia2021
33755090Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML.Blood Adv2021
33775615Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.Transplant Cell Ther2021
34584240An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.Bone Marrow Transplant2021
34428556Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults.Transplant Cell Ther2021
347245632021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.Blood2021
34036237Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome.JCO Precis Oncol2021
33950704Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy.J Clin Oncol2021
34258102Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis.Blood Cancer Discov2021
31539534Cells of Myeloid Origin Partly Mediate the Association between Psoriasis Severity and Coronary Plaque.J Invest Dermatol2020
31666655Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation.Bone Marrow Transplant2020
31804716Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia.Br J Haematol2020
31985806Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia.Blood Adv2020
31860405Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.J Clin Oncol2020
  • 1 - 50 of 123

Recommended Authors

Leo Ruhnke
University Hospital Dresden
Career Start Year 2018
Number of shared co-authors 6
Heidi Altmann
Hopp Children's Cancer Center (KiTZ)
Career Start Year 2017
Number of shared co-authors 7
Adam J Lamble
Seattle Children's Hospital, University of Washington
Career Start Year 2017
Number of shared co-authors 21
Matthieu Duchmann
Assistance Publique-Hopitaux de Paris, Universite de Paris
Career Start Year 2015
Number of shared co-authors 1
Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center
Career Start Year 2011
Number of shared co-authors 6
Thomas K??hnke
Cancer Institute, Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 8
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 11
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 4
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 1
Courtney D DiNardo
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 27
Jamshid S Khorashad
Institute of Cancer Research
Career Start Year 2006
Number of shared co-authors 13
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 31
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 6
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 13
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Career Start Year 2004
Number of shared co-authors 10
Vivian G Oehler
Fred Hutchinson Cancer Center.
Career Start Year 2003
Number of shared co-authors 12
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 5
Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Career Start Year 2000
Number of shared co-authors 14
Lionel Ad??s
Assistance Publique des Hopitaux de Paris (AP-HP)
Career Start Year 1998
Number of shared co-authors 14
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 9
Lukas D Wartman
Washington University School of Medicine in St. Louis
Career Start Year 1998
Number of shared co-authors 2
Thoralf Lange
Hospital Weissenfels
Career Start Year 1994
Number of shared co-authors 16
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 31
Derek L Stirewalt
Fred Hutchinson Cancer Center
Career Start Year 1992
Number of shared co-authors 17
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 4
Claude Gardin
Avicenne Hospital
Career Start Year 1990
Number of shared co-authors 1
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 14
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 37
Soheil Meshinchi
Fred Hutchinson Cancer Research Centre
Career Start Year 1987
Number of shared co-authors 24
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Career Start Year 1984
Number of shared co-authors 11

Collaborators

Sawa Ito
University of Pittsburgh
Co-authored papers 9
Neal S Young
National Heart Lung and Blood Institute Division of Intramural Research
Co-authored papers 7
Uma Borate
The Ohio State University
Co-authored papers 7
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Co-authored papers 6
David A Rizzieri
Duke University Medical Center
Co-authored papers 5
Rafael Bejar
Moores Cancer Center, university of california san diego
Co-authored papers 5
David P Steensma
Novartis Institutes for BioMedical Research
Co-authored papers 5
Ravindra Majeti
Stanford University School of Medicine
Co-authored papers 4
Stephanie Halene
Smilow Cancer Center, Yale University School of Medicine
Co-authored papers 4
Ronan Swords
Oregon Health and Science University
Co-authored papers 3
Michael Heuser
Hannover Medical School
Co-authored papers 3
Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
Co-authored papers 3
Clifton L Dalgard
Uniformed Services University of the Health Sciences
Co-authored papers 3
Jerald P Radich
Fred Hutchinson Cancer Center
Co-authored papers 3
Richard T Maziarz
Oregon Health & Science University
Co-authored papers 3
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Nicola Long
Oregon Health and Science University
Co-authored papers 2
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
James Dibb
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Aashis Thapa
Emory School of Medicine
Co-authored papers 2
Pierrette Lo
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Jessica Leonard
Oregon Health & Science University
Co-authored papers 2
Aurora S Blucher
Knight Cancer Institute, Oregon Health Sciences University
Co-authored papers 2
Richard J Jones
Sidney Kimmel Cancer Center, Johns Hopkins University
Co-authored papers 2
Melissa L Abel
National Cancer Institute, National Institutes of Health
Co-authored papers 2
Justin M Watts
University of Miami, Sylvester Comprehensive Cancer Center
Co-authored papers 2
Joelle Wolf
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Cody Coblentz
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Brian J Druker
Oregon Health & Science University
Co-authored papers 2
Donald A Berry
MD Anderson Cancer Center
Co-authored papers 2
Release 1.2